SCHEMBL29045178

SCHEMBL29045178

COC(=O)C(CCCOc1ccccc1)C(=O)OC

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.74
L3MBTL1 Q9Y468 3/20 0.57
MAPK1 P28482 2/20 0.57
TSHR P16473 2/20 0.57
ALDH1A1 P00352 1/20 0.57
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
RAB9A P51151 2/20 0.53
MAPT P10636 1/20 0.53
PPARG P37231 2/20 0.52
PPARD Q03181 2/20 0.52
PPARA Q07869 2/20 0.52
HPGD P15428 2/20 0.51
RECQL P46063 1/20 0.50
MTNR1A P48039 1/20 0.50
MTNR1B P49286 1/20 0.50
KCNA3 P22001 1/20 0.48
NPC1 O15118 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HDAC1 Q13547 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7637089 0.92 TDP1 (0.64) TDP1L3MBTL1MAPK1TSHRALDH1A1
SCHEMBL7640034 0.88 TDP1 (0.58) TDP1L3MBTL1MAPK1TSHRALDH1A1
SCHEMBL7636953 0.86 TDP1 (0.57) TDP1L3MBTL1MAPK1TSHRALDH1A1
SCHEMBL7636485 0.86 TDP1 (0.57) TDP1L3MBTL1MAPK1TSHRALDH1A1
SCHEMBL7426974 0.85 TDP1 (1.00) TDP1L3MBTL1MAPK1TSHRALDH1A1
SCHEMBL5523873 0.84 TDP1 (0.70) TDP1L3MBTL1MAPK1TSHRALDH1A1
SCHEMBL28275182 0.81 MTNR1A (0.56) TDP1KMT2ARAB9AMAPTPPARG
SCHEMBL7429207 0.81 TDP1 (0.91) TDP1L3MBTL1MAPK1TSHRALDH1A1
SCHEMBL7430736 0.81 TDP1 (0.91) TDP1L3MBTL1MAPK1TSHRALDH1A1
SCHEMBL7571535 0.80 TDP1 (0.88) TDP1L3MBTL1MAPK1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083934-A1 N-ACETYLGALACTOSAMINE (GALNAC)-DERIVED COMPOUNDS AND OLIGONUCLEOTIDES ADARX PHARMACEUTICALS, INC. (US) 2024-03-14 US disclosed
EP-4225322-A1 N-ACETYLGALACTOSAMINE(GALNAC)-DERIVED COMPOUNDS AND OLIGONUCLEOTIDES Adarx Pharmaceuticals, Inc. (US) 2023-08-16 EP disclosed
CN-116546989-A N-acetylgalactosamine (GalNAc) derived compounds and oligonucleotides 阿达尔克斯制药有限公司 2023-08-04 CN disclosed
WO-2022076922-A1 N-ACETYLGALACTOSAMINE(GAlNAc)-DERIVED COMPOUNDS AND OLIGONUCLEOTIDES ADARX PHARMACEUTICALS, INC. (US) 2022-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083934-A1 N-ACETYLGALACTOSAMINE (GALNAC)-DERIVED COMPOUNDS AND OLIGONUCLEOTIDES GALNT1, GALNT13, GALNT6 TDP1 667/4885L3MBTL1 223/4885MAPK1 3371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.